US, Europe submissions for Allergan's Botox in overactive bladder following positive data
This article was originally published in Scrip
Allergan's Botox (onabotulinumtoxinA) met its primary endpoints of reducing daily urinary incontinence (bladder leakage) episodes compared to placebo (p<0.001) in two Phase III clinical trials. Announced as part of its 28 March R&D day for analysts and investors, the trials were in patients with idiopathic overactive bladder (OAB) who have an inadequate response to or are intolerant of an anticholinergic medication. The results could give Allergan another revenue source for its antiwrinkle product.